Drugs / Pooled Mutant KRAS-Targeted Long Peptide Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05254184 | Nov 2022 → Apr 2027 expected | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pooled Mutant KRAS-Targeted Long Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05254184 ↗ |
| Known as | KRAS peptide vaccine | “pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine)” NCT05254184 ↗ |
| Modality | Vaccine | “pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine)” NCT05254184 ↗ |
| Target | KRAS | “KRAS-targeted vaccine” NCT05254184 ↗ |